Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-12
2005-07-12
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S285000
Reexamination Certificate
active
06916823
ABSTRACT:
The present invention relates to the treatment of dopamine-related dysfunction using full D1dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “off-period.” The D1agonist concentration is reduced during the “off-period” to obtain a plasma concentration of agonist that suboptimally activates D1dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises the steps of periodically administering to a patient a full D1agonist with a half-life of up to about 6 hours at a dose resulting in a first plasma concentration of agonist capable of activating D1dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 hours to obtain a second lower plasma concentration of agonist that results in suboptimal activation of D1dopamine receptors for a period of time sufficient to prevent induction of tolerance.
REFERENCES:
patent: 6194423 (2001-02-01), Nichols et al.
“Dinapsoline: Characterization of a D1 Dopamine Receptor Agonist in a Rat Model of Parkinson's Disease,” Gulwadi, et al.J. Pharm. and Exper. Ther. 296: 338-344 (2001).
“Dyskinesias and Tolerance Induced by Chronic Treatment with a D1 Agonist Administered in Pulsatile or Continuous Mode Do Not Correlate with Changes of Putaminal D1 Recptors in Drug-Naive MPTP Monkeys,” Goulet, et al.Brain Res.719: 129-137 (1996).
“Potential Therapeutic Use of the Selective Dopamine D1 Receptor Agonist, A-86929: An Acute Study in Parkinsonian Levodopa-Primed Monkeys,” Grondin et al.Neurology49: 421-426 (1997).
“Time Interval Between Repeated Injections Conditions the Duration of Motor Improvement to Apomorphine in Parkinson's Disease,” Grandas et al.Neurology 42: 1287-1290 (1992).
“Increased or Decreased Locomotor Response in Rats Following Repeated Administration of Apomorphine Depends on Dosage Interval,” Castro et al.Psychopharm.85: 333-339 (1985).
“Time Course of Tolerance to Apomorphine in Parkinsonism,” Gancher et al.Clin. Pharmacol. Ther.52: 504-510 (1992).
“Characterization of the D1 Agonist Dinapsoline in the Unilateral 6-OHDA Lesioned Rat,” Taber et al. Society for Neuroscience Abstr. 26: Abstr. 809.3 (2000).
“The Selective Dopamine D1 Receptor Agonist A-86929 Maintains Efficacy with Repeated Treatment in Rodent and Primate Models of Parkinson's Disease,” Asin et al.J. Pharm. and Exper. Ther. 281: 454-459 (1997).
“Persistent Activation of the Dopamine D1 Receptor Contributes to Prolonged Receptor Desensitization: Studies with A-77636,” Lin et al.J. Pharm. and Exper. Ther.276: 1022-1029 (1996).
Huang Xuemei
Mailman Richard B.
Nichols David E.
Barnes & Thornburg LLP
Kim Jennifer
Padmanabhan Sreeni
Purdue Research Foundation
University of North Carolina at Chapel Hill
LandOfFree
Method of treatment of dopamine-related dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of dopamine-related dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of dopamine-related dysfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3413890